In recent times we have learnt that the Indian government had implemented a ban against common medicines such as Corex, Vicks 500 and now just recently the government made announcement that other medicinal tabs or syrups such as Crocin Cold and Flu, D-Cold Total, Nasivion tablet, Sumo, Oflox, Gastrogyl, Chericof, Nimulid, Kofnil, Dolo Cold, Decoff, O2, Paediatric syrup T-98 and TedyKoff, to be ban as well as to stop manufacturing them.
The government has also urged to stop the sale of fixed dose combination drugs.
A fixed dose combination contains two or more drugs combined in a fixed ratio of doses, available in a single dosage form. The health ministry, had, in a notification on March 12, banned nearly 350 FDCs with immediate effect, following recommendations of an expert committee formed to examine the efficacy of these drug combinations.
According to research firm AIOCD AWACS, the top five therapeutic categories to be impacted include anti-diabetic drugs, respiratory drugs, analgesics, anti-infective and gastro-intestinal drugs. “Government has banned few critical drugs without giving a fair chance to industry. Taking such medicines off the shelf will surprise the consumer and the doctor” said R.C Juneja, CEO of Mankind Pharma, which manufactures popular paediatric syrup T-98 and TedyKoff.
Market estimates reveal that the ban impacts over 2700 medicine brands. While Abbott Healthcare will be worst hit, with an annual loss of Rs 485 crore, other companies including Lupin, Sun Pharma, Glenmark, Wockhardt, Aristo and Intas would also bear the brunt.
While doctors plan on sticking to single formulation drugs instead of multiple combinations since they are confused over the implementation of the ban, “The ban is on combination drugs. Hence we need to stick to single drug and not combos,” said Anoop Misra, chairman, Fortis CDOC Hospital for Diabetes and Allied Sciences.